Article

Soluble endoglin for the prediction of preeclampsia in a high risk cohort

Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.
Hypertension in Pregnancy (Impact Factor: 1.19). 08/2010; 29(3):330-41. DOI: 10.3109/10641950902968684
Source: PubMed

ABSTRACT To evaluate soluble endoglin (sEng) and the soluble fms-like tyrosine kinase 1 (sFlt1) to placental growth factor (PlGF) ratio for the prediction of preeclampsia in high-risk women, and to evaluate differences in sEng between women with high-risk singleton and multiple gestation pregnancies.
We collected serial serum specimens from 119 women at high preeclampsia risk. sEng, sFlt1 and PlGF were measured by ELISA.
Among subjects who did not develop preeclampsia, mean serum sEng was significantly higher in those with multiple gestation pregnancies vs. high-risk singletons. Among women with singleton gestations, mean serum sEng was higher in subjects who developed early-onset (<34 weeks) and late-onset (>or= 34 weeks) preeclampsia, as compared with subjects without preeclampsia, from 22 weeks and 28 weeks gestation onward, respectively. The within-woman rate of change of sEng was also higher in women who later developed preeclampsia.
sEng is higher in women with multiple gestations vs. high-risk singleton pregnancies. In high-risk women, serum sEng is increased prior to preeclampsia onset.

0 Followers
 · 
108 Views
  • Source
    • "In the second stage, the ischemic and hypoxic placenta releases anti-angiogenic factors such as soluble Fms-like tyrosine kinase-1 (sFlt-1), soluble endoglin (sEng), prostaglandins and cytokines into the maternal circulation and dysregulates the production of pro-angiogenic factors including vascular endothelial growth factor (VEGF), placental growth factor (PlGF), fibroblast growth factor (FGF), transforming growth factor-B (TGF-B) and insulin-like growth factor I (IGF-I) [5] [6] [7] [8]. It is clear that the levels of sFlt1, sEng and other anti-angiogenic factors are increased and the concentrations of VEGF, PlGF and other pro-angiogenic factors are decreased in preeclampsia [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22]. These changes induce systemic endothelial dysfunction and inflammatory response leading to elevated systemic vascular resistance, vasoconstriction, and activation of the coagulation cascade [23]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In pre-clinical stage of preeclampsia, placental angiogenesis is impaired leading to hypoxic placenta and dysregulation of pro- and anti-angiogenetic factors. As a consequence, these cause elevated systemic vascular resistance, vasoconstriction and hypertension in clinical stage of preeclampsia. Dysregulation of microRNAs (miRNAs) has been observed among preeclampsia patients and they are involved in several aspects of preeclampsia pathogenesis.
    Egyptian Journal of Medical Human Genetics 04/2015; 183. DOI:10.1016/j.ejmhg.2015.03.006
  • [Show abstract] [Hide abstract]
    ABSTRACT: A model-based image understanding and spatial reasoning system (SRS) has been integrated with a robot planner to provide a testbed for autonomously sensing and responding to complex but well-structured environments. The entire system operates in such a way that the robot planner requests state information for entities on a task panel from the SRS. State information may consist of the location or orientation of a latch or door on the panel or it may reflect a particular function, such as whether a latch is open or closed. Examples which illustrate the operation of the entire system with actual robotic and vision hardware are provided. The advantages and disadvantages of active/passive markers and teleoperation within the context of the integrated system are also discussed
    Robotics and Automation, 1989. Proceedings., 1989 IEEE International Conference on; 06/1989
  • [Show abstract] [Hide abstract]
    ABSTRACT: Microangiopathic disorders present with thrombocytopenia, hemolytic anemia, and multiorgan damage. In pregnancy, these disorders present a challenge both diagnostically and therapeutically, with widely overlapping clinical scenarios and disparate treatments. Although rare, a clear understanding of these diseases is important because devastating maternal and fetal outcomes may ensue if there is misdiagnosis and improper treatment. Microangiopathic disorders presenting in pregnancy are thus best assessed and treated by both obstetric and hematology teams. As a better understanding of the pathophysiology underlying each of the disease processes is gained, new diagnostic testing and therapies will be available, which will lead to improved outcomes.
    Hematology/oncology clinics of North America 04/2011; 25(2):311-22, viii. DOI:10.1016/j.hoc.2011.01.005 · 2.07 Impact Factor
Show more